Drugs / Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00487305 | Jun 2007 → Jul 2023 | follicular lymphoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00487305 ↗ |
| Modality | Vaccine | “The purpose of this study is to compare the safety and immune activity of three doses of tumor vaccine.” NCT00487305 ↗ |
| Route | Subcutaneous | “the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.” NCT00487305 ↗ |